본문 바로가기

Inflammation in MASLD progression and cancer

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
JHEP REPORTS7(8) · 2025
피인용
Web of Science 56Scopus 58
FWCI (Scopus)
5.93
JCR IF
JCR 2024 7.5
ISSN
2589-5559

저자

  1. 김연수제1저자Pusan Natl Univ, Coll Pharm, 63-2 Busandaehak Ro, Busan 46241, South Korea
  2. 박윤서Pusan Natl Univ, Coll Pharm, 63-2 Busandaehak Ro, Busan 46241, South Korea
  3. Rho, HyunsooEwha Womans Univ, Coll Pharm, Grad Sch Pharmaceut Sci, Seoul, South Korea
  4. Yao, TiantianNIAAA, Lab Liver Dis, NIH, Bethesda, MD USA
  5. Gao, BinNIAAA, Lab Liver Dis, NIH, Bethesda, MD USA
  6. 황성환교신저자Pusan Natl Univ, Coll Pharm, 63-2 Busandaehak Ro, Busan 46241, South Korea

초록

Steatotic liver diseases include metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease, and metabolic dysfunction and alcohol-related liver disease (MetALD), encompassing a spectrum of metabolic liver disorders that range from steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Steatotic liver disease is primarily driven by alcohol consumption and metabolic dysfunction, making it the leading cause of chronic liver disease. Steatosis is defined by excessive fat accumulation in the liver without significant liver injury or inflammation. In contrast, inflammation is the predominant factor that drives the progression of steatosis to steatohepatitis and, ultimately, to cancer. In this review, we summarise the current understanding of the inflammatory mechanisms underlying the pathogenesis of MASLD and explore molecular targets that may offer the potential for pharmacological intervention. Additionally, given the pathological similarities between MASLD and MetALD, relevant inflammatory pathways in MetALD are briefly discussed to underscore both commonalities and key distinctions between the two conditions.

키워드

adipose tissuechemokinescytokinesgut-liver axisimmune cellslipotoxicityNONALCOHOLIC FATTY LIVERT-CELLSALCOHOL-CONSUMPTIONDENDRITIC CELLSHEPATOCELLULAR-CARCINOMARECEPTORS FXRNK CELLSSTEATOHEPATITISMICEFIBROSIS

식별자

Scopus EID
2-s2.0-105009078228
WoS UID
001532598200001